{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:07:09Z","timestamp":1779365229861,"version":"3.53.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100001126","name":"Geisinger Health","doi-asserted-by":"publisher","award":["SRC-L-85"],"award-info":[{"award-number":["SRC-L-85"]}],"id":[{"id":"10.13039\/100001126","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pilot Feasibility Stud"],"DOI":"10.1186\/s40814-026-01828-4","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:58:53Z","timestamp":1777337933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of a hybrid online\/in-person implementation of the complete health improvement program on biomarkers, biometrics, and drug utilization in type 2 diabetes mellitus: a pilot randomized-controlled trial"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2723-9791","authenticated-orcid":false,"given":"Thomas","family":"Morland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"McNally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"VanEnkevort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn","family":"Wilk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Persing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Blessing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Lester","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"1828_CR1","doi-asserted-by":"publisher","DOI":"10.2337\/dci23-0085","author":"ED Parker","year":"2023","unstructured":"Parker ED, Lin J, Mahoney T, et al. Economic costs of diabetes in the U.S. in 2022. Diabetes Care. 2023. https:\/\/doi.org\/10.2337\/dci23-0085.","journal-title":"Diabetes Care"},{"key":"1828_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/dme.14122","volume":"37","author":"H Dambha\u2010miller","year":"2020","unstructured":"Dambha\u2010miller H, Day AJ, Strelitz J, Irving G, Griffin SJ, Wiley. Behaviour change, weight loss and remission of type 2 diabetes: a community\u2010based prospective cohort study. Diabet Med. 2020;37:681.","journal-title":"Diabet Med"},{"key":"1828_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","volume":"391","author":"MEJ Lean","year":"2018","unstructured":"Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391:541\u201351.","journal-title":"Lancet"},{"key":"1828_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2213-8587(23)00385-6","volume":"12","author":"ME Lean","year":"2024","unstructured":"Lean ME, Leslie WS, Barnes AC, et al. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol. 2024;12:233 Elsevier BV.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1828_CR5","first-page":"A05","volume":"3","author":"SG Aldana","year":"2006","unstructured":"Aldana SG, Greenlaw RL, Diehl HA, et al. The behavioral and clinical effects of therapeutic lifestyle change on middle-aged adults. Prev Chronic Dis. 2006;3:A05.","journal-title":"Prev Chronic Dis"},{"key":"1828_CR6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jada.2004.12.007","volume":"105","author":"SG Aldana","year":"2005","unstructured":"Aldana SG, Greenlaw RL, Diehl HA, et al. Effects of an intensive diet and physical activity modification program on the health risks of adults. J Am Diet Assoc. 2005;105:371\u201381.","journal-title":"J Am Diet Assoc"},{"key":"1828_CR7","first-page":"64","volume":"1","author":"D Morton","year":"2014","unstructured":"Morton D, Rankin P, Kent L, Dysinger W. The complete health improvement program (CHIP): history, evaluation, and outcomes. Am J Lifestyle Med. 2014;1:64\u201373.","journal-title":"Am J Lifestyle Med"},{"key":"1828_CR8","first-page":"293","volume":"117","author":"C Remy","year":"2017","unstructured":"Remy C, Shubrook JH, Nakazawa M, Drozek D. Employer-funded complete health improvement program: preliminary results of biomarker changes. J Am Osteopath Assoc. 2017;117:293\u2013300.","journal-title":"J Am Osteopath Assoc"},{"key":"1828_CR9","first-page":"84","volume":"116","author":"C Leibold","year":"2016","unstructured":"Leibold C, Shubrook JH, Nakazawa M, Drozek D. Effectiveness of the complete health improvement program in reducing risk factors for cardiovascular disease in an appalachian population. J Am Osteopath Assoc. 2016;116:84\u201391.","journal-title":"J Am Osteopath Assoc"},{"key":"1828_CR10","first-page":"5","volume":"15","author":"D Shurney","year":"2012","unstructured":"Shurney D, Hyde S, Hulsey K, Elam R, Cooper A, Groves J. Chip lifestyle program at Vanderbilt University demonstrates an early ROI for a diabetic cohort in a workplace setting: a case study. J Manag Care Med. 2012;15:5\u201315.","journal-title":"J Manag Care Med"},{"key":"1828_CR11","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1828_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653\u201362.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Pilot and Feasibility Studies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40814-026-01828-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-026-01828-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-026-01828-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:24:12Z","timestamp":1779362652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40814-026-01828-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1828"],"URL":"https:\/\/doi.org\/10.1186\/s40814-026-01828-4","relation":{},"ISSN":["2055-5784"],"issn-type":[{"value":"2055-5784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Geisinger\u2019s institutional review board (IRB) and was conducted in accordance with principles of the Declaration of Helsinki. All participants underwent informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individual research participant\u2019s personally identifiable data are included in the manuscript (e.g. images, or videos), so consent for publication of same is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Morland does research funded by Tempus Laboratories, iRhythm, and Grail. Dr. Morland\u2019s wife works at United Therapeutics and is a shareholder. Dr. Morland is on the Board of Directors at the Miller Center for Recreation and Wellness. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}